These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

246 related items for PubMed ID: 28739841

  • 21. Regulation of cardiac fatty acids metabolism in transgenic mice overexpressing bovine GH.
    Bogazzi F, Raggi F, Ultimieri F, Russo D, D'Alessio A, Manariti A, Brogioni S, Manetti L, Martino E.
    J Endocrinol; 2009 Jun; 201(3):419-27. PubMed ID: 19342398
    [Abstract] [Full Text] [Related]

  • 22. Myocardial fatty acid metabolism in health and disease.
    Lopaschuk GD, Ussher JR, Folmes CD, Jaswal JS, Stanley WC.
    Physiol Rev; 2010 Jan; 90(1):207-58. PubMed ID: 20086077
    [Abstract] [Full Text] [Related]

  • 23. Fatty acid metabolism is enhanced in type 2 diabetic hearts.
    Carley AN, Severson DL.
    Biochim Biophys Acta; 2005 May 15; 1734(2):112-26. PubMed ID: 15904868
    [Abstract] [Full Text] [Related]

  • 24. High fat diet induced diabetic cardiomyopathy.
    Dirkx E, Schwenk RW, Glatz JF, Luiken JJ, van Eys GJ.
    Prostaglandins Leukot Essent Fatty Acids; 2011 Nov 15; 85(5):219-25. PubMed ID: 21571515
    [Abstract] [Full Text] [Related]

  • 25. Acetylation control of cardiac fatty acid β-oxidation and energy metabolism in obesity, diabetes, and heart failure.
    Fukushima A, Lopaschuk GD.
    Biochim Biophys Acta; 2016 Dec 15; 1862(12):2211-2220. PubMed ID: 27479696
    [Abstract] [Full Text] [Related]

  • 26. Genetic modification of the heart: transgenic modification of cardiac lipid and carbohydrate utilization.
    Hartil K, Charron MJ.
    J Mol Cell Cardiol; 2005 Oct 15; 39(4):581-93. PubMed ID: 16140322
    [Abstract] [Full Text] [Related]

  • 27. Targets for modulation of fatty acid oxidation in the heart.
    Lopaschuk GD.
    Curr Opin Investig Drugs; 2004 Mar 15; 5(3):290-4. PubMed ID: 15083595
    [Abstract] [Full Text] [Related]

  • 28. Nuclear receptor signaling and cardiac energetics.
    Huss JM, Kelly DP.
    Circ Res; 2004 Sep 17; 95(6):568-78. PubMed ID: 15375023
    [Abstract] [Full Text] [Related]

  • 29. Protective mechanisms of mitochondria and heart function in diabetes.
    Aon MA, Tocchetti CG, Bhatt N, Paolocci N, Cortassa S.
    Antioxid Redox Signal; 2015 Jun 10; 22(17):1563-86. PubMed ID: 25674814
    [Abstract] [Full Text] [Related]

  • 30. Metabolic toxicity of the heart: insights from molecular imaging.
    Iozzo P.
    Nutr Metab Cardiovasc Dis; 2010 Mar 10; 20(3):147-56. PubMed ID: 20031381
    [Abstract] [Full Text] [Related]

  • 31. Defective energy metabolism of the heart in diabetes.
    Taegtmeyer H, Passmore JM.
    Lancet; 1985 Jan 19; 1(8421):139-41. PubMed ID: 2857216
    [No Abstract] [Full Text] [Related]

  • 32. Methods for the Determination of Rates of Glucose and Fatty Acid Oxidation in the Isolated Working Rat Heart.
    Bakrania B, Granger JP, Harmancey R.
    J Vis Exp; 2016 Sep 28; (115):. PubMed ID: 27768055
    [Abstract] [Full Text] [Related]

  • 33. Cardiac metabolism and its interactions with contraction, growth, and survival of cardiomyocytes.
    Kolwicz SC, Purohit S, Tian R.
    Circ Res; 2013 Aug 16; 113(5):603-16. PubMed ID: 23948585
    [Abstract] [Full Text] [Related]

  • 34. Good and bad consequences of altered fatty acid metabolism in heart failure: evidence from mouse models.
    Abdurrachim D, Luiken JJ, Nicolay K, Glatz JF, Prompers JJ, Nabben M.
    Cardiovasc Res; 2015 May 01; 106(2):194-205. PubMed ID: 25765936
    [Abstract] [Full Text] [Related]

  • 35. What are the biochemical mechanisms responsible for enhanced fatty acid utilization by perfused hearts from type 2 diabetic db/db mice?
    Carley AN, Severson DL.
    Cardiovasc Drugs Ther; 2008 Apr 01; 22(2):83-9. PubMed ID: 18247111
    [Abstract] [Full Text] [Related]

  • 36. Cardiac energy dependence on glucose increases metabolites related to glutathione and activates metabolic genes controlled by mechanistic target of rapamycin.
    Schisler JC, Grevengoed TJ, Pascual F, Cooper DE, Ellis JM, Paul DS, Willis MS, Patterson C, Jia W, Coleman RA.
    J Am Heart Assoc; 2015 Feb 24; 4(2):. PubMed ID: 25713290
    [Abstract] [Full Text] [Related]

  • 37. A "PET" area of interest: myocardial metabolism in human systolic heart failure.
    Kadkhodayan A, Coggan AR, Peterson LR.
    Heart Fail Rev; 2013 Sep 24; 18(5):567-74. PubMed ID: 23180281
    [Abstract] [Full Text] [Related]

  • 38. Targeting fatty acid metabolism in heart failure: is it a suitable therapeutic approach?
    Arumugam S, Sreedhar R, Thandavarayan RA, Karuppagounder V, Watanabe K.
    Drug Discov Today; 2016 Jun 24; 21(6):1003-8. PubMed ID: 26905600
    [Abstract] [Full Text] [Related]

  • 39. Effect of BM 17.0744, a PPARalpha ligand, on the metabolism of perfused hearts from control and diabetic mice.
    Aasum E, Cooper M, Severson DL, Larsen TS.
    Can J Physiol Pharmacol; 2005 Feb 24; 83(2):183-90. PubMed ID: 15791292
    [Abstract] [Full Text] [Related]

  • 40. Diabetic cardiomyopathy.
    Feuvray D.
    Arch Mal Coeur Vaiss; 2004 Mar 24; 97(3):261-5. PubMed ID: 15106750
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.